

CHARITY REGISTRATION NUMBER: 1148034

COMPANY REGISTRATION NUMBER: 07842342

CILIOPATHY ALLIANCE

Unaudited Financial Statements

(A company limited by guarantee)

31 March 2026

CILIOPATHY ALLIANCE

Financial Statements

Year ended 31 March 2026

	Page
Trustees' annual report (incorporating the directors' report)	1
Independent examiner's report to the trustees	8
Statement of financial activities	9
Statement of financial position	10
Statement of cash flows	11
Notes to the Financial Statements	12
Detailed Statement of Financial Activities	17

CILIOPATHY ALLIANCE

Trustees' Annual Report

Year ended 31 March 2026

The trustees present their report and the unaudited financial statements of the charity for the year ended 31 March 2026.

Reference and Administrative Details

Charity Name:	CILIOPATHY ALLIANCE
Charity Number:	1148034
Company Number:	07842342
Principal Address:	INSTITUTE OF CHILD HEALTH 30 GUILDFORD STREET LONDON WC1N 1EH
Website:	www.ciliopathyalliance.org
Email:	info@ciliopathyalliance.org
Trustees:	Professor Hannah Margaret Mitchison (Chairperson) Dr Rhoda Akilapa (appointed 21 October 2025) Fiona Jayne Copeland Dr Elizabeth Forsythe (resigned 3 July 2026) Audrey Irene Hughes (appointed 21 October 2025) Tonia Louise Hymers Kerry Leeson-Beevers Dr Roly David Megaw Temitope Oyedero Oyefuga (resigned 18 September 2025)
Scientific Advisory Board:	Chaired by Professor Philip Beales
Bankers:	Lloyds Bank
Accountants:	Burton Bandini Ltd 30a High Street Stony Stratford Milton Keynes MK11 1AF

CILIOPATHY ALLIANCE

Trustees' Annual Report *(continued)*

Year ended 31 March 2026

The year represented a period of transition from recovery and consolidation into delivery against a clearer strategic plan. Following the development of the 2025-2028 Strategic and Business Plan, the Alliance began organising its work around five themes: digital transformation and communications; research facilitation and partnerships; advocacy and stakeholder engagement; governance and capacity building; and fundraising and financial sustainability.

Chair's introduction

During 2025-26, the Ciliopathy Alliance continued to bring together patient organisations, people with lived experience, clinicians and researchers to improve understanding of ciliopathies and ensure that patient priorities are heard. The breadth of the year's work demonstrates how much can be achieved by a small, committed charity when trustees, volunteers, partner organisations and supporters work together.

Our focus has been on strengthening the foundations of the Alliance so that we can operate more sustainably and increase our impact. This has included adopting a new strategy, improving our communications, expanding volunteer and intern involvement, participating in national rare disease policy conversations and continuing to support research partnerships. The Board is grateful to everyone who has contributed time, expertise and lived experience during the year.

Objectives and aims

The Ciliopathy Alliance is a UK-based umbrella organisation for patient support groups, researchers, doctors and allied health professionals representing patients and families affected by diseases caused by defects in the function or structure of cilia. Ciliopathies can affect multiple systems, including vision, hearing, kidneys, lungs, heart, fertility, weight regulation and metabolism.

The charitable object of the Alliance is to relieve sickness and promote and protect good health of children and adults living with ciliopathies, with a view to improving their conditions of life. In practice, the Alliance seeks to promote knowledge, support patient involvement in research, provide accessible information, connect patient groups and professionals, and advocate for better diagnosis, treatment and care.

Performance and achievements during 2025-26

The following section is structured against the five strategic themes adopted in the 2025-2028 Strategic and Business Plan. This approach demonstrates how activity undertaken during the year contributed to the longer-term direction agreed by the Board.

1. Digital transformation and communications

The Alliance continued to strengthen its digital presence during the year. Website updates, news stories, patient perspectives, trustee profiles and regular newsletters were used to share information with patients, families, researchers, clinicians and member organisations. A key objective was to make the Alliance more visible and more useful to people who may not have access to a disease-specific support group.

Newsletter activity became more regular and more strategic. Updates during the year included information about the new strategy, webinars, research activity, trustee recruitment, volunteer involvement and opportunities for the community to engage with wider rare disease policy work.

The Alliance also regained and reactivated social media channels, including Facebook, and considered the role of emerging platforms such as BlueSky. This work helped reconnect the Alliance with existing audiences and reach new organisations, including international interest from the Heterotaxy Foundation, which later joined the Alliance.

CILIOPATHY ALLIANCE

Trustees' Annual Report *(continued)*

Year ended 31 March 2026

Volunteer and intern projects contributed to communications planning, website review actions and social media development. This combination of practical delivery and strategic planning has created a stronger basis for communications in 2026-27.

2. Research facilitation and partnerships

Research facilitation remained central to the work of the Alliance. During 2025-26, the charity continued to act as patient partner in major research initiatives, including TheRaCiL and CiliaREN. These roles help ensure that people affected by ciliopathies are represented in research design, communication and patient involvement activities.

We have conducted a number of research-related activities including letters of support for the Living with PCD research programme, a Diabetes UK grant investigating a role of cilia in the regulation of AMPK in pancreatic cells, and a kidney modelling grant/project. The Alliance also sent a survey to patient groups relating to patient organisations and research.

The Alliance supported the UK Cilia and Centrosome Network meeting in June 2025 and used the meeting to raise awareness of the new strategy and demonstrate its involvement in research partnerships. Kerry Leeson-Beevers updated the group about the Alliance strategy, and Temitope Oyefuga reflected publicly on attending her first cilia scientific meeting as Treasurer.

In January 2026, the Alliance organised laboratory visits for interns and a volunteer to the Institute of Child Health and the Royal Brompton Hospital. The visit provided insight into research and diagnostic pathways in Primary Ciliary Dyskinesia and demonstrated the value of linking researchers, students and patient advocacy organisations.

"What stood out most was how no single technique tells the full story. Effective diagnosis and progress towards treatment rely on integrating clinical insight, advanced imaging, genetics and laboratory research."

3. Advocacy and stakeholder engagement

The Alliance continued to represent the ciliopathy community within the wider rare disease landscape. In February 2026, trustees Elizabeth Forsythe and Kerry Leeson-Beevers attended the Westminster Rare Disease Day reception at the House of Commons. The website records that the theme of Rare Disease Day 2026 was equity and highlights discussion of the 2026 England Rare Disease Action Plan and NICE Quality Standards for Rare Diseases.

The Chair, Hannah Mitchison, also attended the launch of the LifeArc, Genetic Alliance UK and Beacon for Rare Diseases policy report, More Trials Better Data Faster Access, at Parliament in March 2026. This aligned with the Alliance's strategic focus on advocacy, better access to research and stronger policy engagement for rare disease communities.

Patient stories became an important part of the Alliance's engagement approach. In April 2026, shortly after the reporting year, the website published a patient story about living with Retinitis Pigmentosa. The story highlighted the impact of diagnosis, loss of independence, financial hardship, art, support and renewed purpose. It also invited others to share their stories, supporting the Alliance's aim to give lived experience greater visibility.

The Alliance also began work with Genetic Alliance UK to hold a Future for Rare workshop to gather community input on the future of the UK Rare Diseases Framework.

CILIOPATHY ALLIANCE

Trustees' Annual Report *(continued)*

Year ended 31 March 2026

4. Governance and capacity building

A major achievement of the year was the development and adoption of the Alliance's 2025-2028 Strategic and Business Plan. The action list records that strategy discussions were supported by Cranfield Trust engagement, trustee meetings, review of priorities and agreement to use volunteer and intern resource to progress projects including communications planning, branding and fundraising.

Governance activity during the year included trustee meetings, AGM planning, policy review, operational documentation and improvements to Microsoft 365 administration. The Alliance also reviewed membership visibility, trustee onboarding and administrative processes. These activities support a more resilient operating model as the charity grows.

Trustee changes were also implemented. Audrey Hughes joined the Board following involvement with CiliaREN and representation of the PKD community. Rhoda Akilapa joined the committee at the AGM.

The Alliance continued to seek a Treasurer to strengthen financial oversight and succession planning.

5. Fundraising and financial sustainability

Building financial sustainability was a key priority in the strategic plan. During 2025-26 the Alliance modernised its banking and fundraising infrastructure. The action list records a change of bank account to Lloyds, the establishment of savings accounts, the completion of PayPal changes and the setup of JustGiving, including subsequent registration to collect Gift Aid.

The Board also sought external fundraising advice from Louise Fish, former Chief Executive of Genetic Alliance UK. Work began to identify organisations that might support an alliance-style charity and to develop a more structured fundraising approach. This work remains important because the strategic plan identifies the need to diversify unrestricted income, develop grant partnerships and build reserves equivalent to six months of core costs by year three.

The Alliance continued to operate with a lean model, relying significantly on trustee, volunteer and intern contributions. This kept costs proportionate while allowing development work to progress. However, the Board recognises that sustainable funding will be required to support future growth, improve communications, reimburse patient involvement and strengthen administrative capacity.

CILIOPATHY ALLIANCE

Trustees' Annual Report *(continued)*

Year ended 31 March 2026

Volunteer and intern contributions

Volunteers, trustees and interns were central to delivery during 2025-26. The Alliance expanded its volunteer network through Reach Volunteering and Keele University, bringing in additional capacity for communications, research engagement, website development, social media, governance and operational planning.

Three Keele University interns joined the Alliance in November 2025. Each student completed 75 hours of work over four months primarily helping us with our communication plans and updating the website content.

Volunteer support also strengthened website content, patient stories and trustee profiles. Adrian M, recruited through Reach Volunteering, supported copy for the website and contributed to patient story development.

"Meeting people from outside the lab is incredibly encouraging for us, and it helps me carry on with what I am doing, knowing I am not alone and that there is a real and urgent need for a cure."

"Experiences like this continue to shape my interest in clinical research, diagnostics and healthcare innovation within rare disease medicine."

The trustees record their sincere thanks to all volunteers, interns, advisers, researchers and supporters who contributed time and expertise. Their contribution enabled the Alliance to progress work that would not otherwise have been possible within existing resources.

Plans for 2026-27

During 2026-27 the Alliance will continue implementation of the second year of the 2025-2028 Strategic and Business Plan. The focus will be on moving from foundational work into sustained delivery across communications, research, advocacy, governance and fundraising.

Strategic theme	2026-27 priority	Intended outcome
Digital transformation	Implement website review actions, continue newsletters, strengthen social media and member communications.	Clearer information, better engagement (in particular with research programmes) and stronger community visibility.
Research partnerships	Continue patient partner roles in TheRaCiL and CiliaREN, support Cilia27 patient planning and develop partnerships.	Patient priorities embedded in research and international collaboration.
Advocacy	Work with Genetic Alliance UK and partners to gather community views and influence rare disease policy.	Ciliopathy voices reflected in wider rare disease conversations.
Governance	Recruit a Treasurer, strengthen trustee onboarding and complete policy reviews.	Greater organisational resilience and clearer operating processes.
Fundraising	Develop grant, corporate and individual giving opportunities using improved donation infrastructure.	More sustainable income to deliver strategic ambitions.

CILIOPATHY ALLIANCE

Trustees' Annual Report *(continued)*

Year ended 31 March 2026

Financial review

The year ended 31 March 2026 was one of strategic investment and organisational development. Building on the foundations established in the previous year, the Board focused on implementing priorities identified within the 2025-2028 Strategic and Business Plan. This included investment in governance, communications, volunteer recruitment, fundraising infrastructure and research engagement activities designed to strengthen the Alliance's long-term sustainability and increase its impact for patients and families affected by ciliopathies.

Throughout the year, the charity continued to operate primarily through the dedication of volunteers, trustees and partners, ensuring that available resources were directed towards activities supporting patient engagement, research collaboration, advocacy and awareness raising. Key financial developments included the introduction of new donation platforms, improved banking arrangements, enhanced financial controls and the development of a structured approach to future fundraising.

Summary financial position

Financial summary	2025-26	2024-25 comparative
Income	£7,821	£1,689
Expenditure	£12,271	£10,352
Surplus/(deficit)	(£4,450)	(£8,663)
Funds brought forward	£26,442	£35,105
Funds carried forward	£21,992	£26,442

The trustees are satisfied that the charity remains on a sound financial footing and that resources available to the Alliance have been managed responsibly and in accordance with its charitable objectives. The Board recognises that diversifying income streams and increasing unrestricted funding will be essential to achieving the ambitions set out within the 2025-2028 Strategic and Business Plan.

CILIOPATHY ALLIANCE

Trustees' Annual Report *(continued)*

Year ended 31 March 2026

Structure, governance and management


The Ciliopathy Alliance was established as a company limited by guarantee in 2011 and registered with the Charity Commission in 2012. The charity is governed by its Memorandum and Articles of Association dated 12 October 2011, as amended by special resolutions on 19 June 2012 and 8 March 2019. In the event of the charity being wound up, the liability of each member is limited to a sum not exceeding £10.

The trustees of the charity, who are also directors of the limited company, are responsible for governance and strategic direction. Trustees meet approximately quarterly and communicate between meetings by email. A members' meeting is held at the AGM to share information and receive input into the charity's strategy and activities.

Trustees serving during 2025-26 were Professor Hannah Mitchison (Chair), Fiona Copeland BEM, Tonia Hymers, Kerry Leeson-Beevers, Dr Roly Megaw, Dr Elizabeth Forsythe, Temitope Oyefuga (until September 2025), and Dr Rhoda Akilapa and Audrey Hughes (both from October 2025). The Alliance continues to seek additional trustee and Treasurer support to strengthen governance and financial resilience.

All charitable activities are undertaken to further charitable purposes for public benefit. The trustees confirm that they have had regard to the Charity Commission's guidance on public benefit when reviewing the charity's aims and objectives and in planning activities.

This report has been prepared in accordance with the provisions applicable to companies entitled to the small companies exemption under section 415A of the Companies Act 2006. The trustees' annual report was approved by the board of trustees on 1 October 2026 and signed on its behalf by:



Hannah Margaret Mitchison
Chairperson

CILIOPATHY ALLIANCE

Independent Examiner's Report to the Trustees of CILIOPATHY ALLIANCE

Year ended 31 March 2026

I report to the trustees on my examination of the financial statements of CILIOPATHY ALLIANCE ('the company') for the year ended 31 March 2026.

Responsibilities and basis of report

As the trustees of the company (and also its directors for the purposes of company law) you are responsible for the preparation of the financial statements in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the financial statements of the company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of the company's financial statements as carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

Independent examiner's statement

I have completed my examination. I confirm that no material matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

1. accounting records were not kept in respect of the company as required by section 386 of the 2006 Act; or
2. the financial statements do not accord with those records; or
3. the financial statements do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the financial statements give a 'true and fair' view which is not a matter considered as part of an independent examination; or
4. the financial statements have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities applicable to charities preparing their accounts in accordance with FRS 102 (Charities SORP (FRS 102)).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

Independent Examiner

A handwritten signature in black ink, appearing to read 'Carol Bandini', with a stylized initial 'CB'.

Carol Bandini
FMAAT

CILIOPATHY ALLIANCE

Statement of Financial Activities

Year ended 31 March 2026

				2026	2025
	Note	Unrestricted funds £	Restricted funds £	Total funds £	Total funds £
Income and endowments					
Donations and legacies		686	—	686	1,477
Investment income		148	—	148	212
Restricted Grants	5	—	6,987	6,987	—
Total income		<u>834</u>	<u>6,987</u>	<u>7,821</u>	<u>1,689</u>
Expenditure					
Fundraising Expenses		2,400	—	2,400	7,141
Expenditure on charitable activities		2,371	3,832	6,203	3,211
Governance costs		3,668	—	3,668	—
Total expenditure		<u>8,439</u>	<u>3,832</u>	<u>12,271</u>	<u>10,352</u>
Net income and net movement in funds		<u>(7,605)</u>	<u>3,155</u>	<u>(4,450)</u>	<u>(8,663)</u>
Reconciliation of funds					
Total funds brought forward		24,965	1,477	26,442	35,105
Total funds carried forward		<u>17,360</u>	<u>4,632</u>	<u>21,992</u>	<u>26,442</u>

The statement of financial activities includes all gains and losses recognised in the year. All income and expenditure derive from continuing activities.

CILIOPATHY ALLIANCE

Statement of Financial Position

Year ended 31 March 2026

	Note	2026 £	2025 £
Fixed assets			
Tangible fixed assets		—	—
Current assets			
Debtors		—	—
Cash at bank and in hand		27,075	28,644
		<u>27,075</u>	<u>28,644</u>
Creditors: amounts falling due within one year	4	<u>5,083</u>	<u>2,202</u>
Net current assets		<u>21,992</u>	<u>26,442</u>
Total assets less current liabilities		<u>21,992</u>	<u>26,442</u>
Net assets		<u>21,992</u>	<u>26,442</u>
Funds of the charity			
Restricted funds		4,632	1,477
Unrestricted funds		17,360	24,965
Total charity funds		<u>21,992</u>	<u>26,442</u>

Company registration number: 07842342

For the year ending 31 March 2026 the charitable company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.


Directors' responsibilities:

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

These financial statements were approved by the board of trustees and authorised for issue on 1 October 2026 and are signed on behalf of the board by:



Hannah Margaret Mitchison
Chairperson

CILIOPATHY ALLIANCE

Statement of Cash Flows

Year ended 31 March 2026

	2026 £	2025 £
Cash flows from operating activities		
Net income	(4,450)	(8,663)
<i>Adjustments for:</i>		
Depreciation of tangible fixed assets	—	—
Other interest receivable and similar income	(148)	(212)
Accrued income	—	—
<i>Changes in:</i>		
Trade and other debtors	—	—
Trade and other creditors	2,881	2,202
Cash generated from operations	(1,717)	(6,673)
Interest received	148	212
Net cash from operating activities	<u>(1,569)</u>	<u>(6,461)</u>
Cash flows from investing activities		
Purchase of tangible assets	—	—
Net cash used in investing activities	<u>—</u>	<u>—</u>
Net increase in cash and cash equivalents	(1,569)	(6,461)
Cash and cash equivalents at beginning of year	28,644	35,105
Cash and cash equivalents at end of year	<u>27,075</u>	<u>28,644</u>

CILIOPATHY ALLIANCE

Notes to the Financial Statements

Year ended 31 March 2026

1. General information

The charity is a public benefit entity and a charitable company limited by guarantee, registered in England and Wales (company number 07842342) and registered with the Charity Commission (charity number 1148034). The address of the registered office is INSTITUTE OF CHILD HEALTH, 30 GUILDFORD STREET, LONDON, WC1N 1EH. The charitable company is governed by its Memorandum and Articles of Association dated 12 October 2011, as amended on 19 June 2012 and 8 March 2019. In the event of the charitable company being wound up, the liability of each member is limited to a sum not exceeding £10.

2. Statement of compliance

These financial statements have been prepared in compliance with FRS 102, 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland', the Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (Charities SORP (FRS 102)) and the Companies Act 2006.

3. Accounting policies

Basis of preparation

The financial statements have been prepared on the historical cost basis, as modified by the revaluation of certain financial assets and liabilities and investment properties measured at fair value through income or expenditure.

The financial statements are prepared in sterling, which is the functional currency of the entity.

Going concern

There are no material uncertainties about the charity's ability to continue.

Fund accounting

Unrestricted funds are available for use at the discretion of the trustees to further any of the charity's purposes.

Designated funds are unrestricted funds earmarked by the trustees for particular future project or commitment.

Restricted funds are subjected to restrictions on their expenditure declared by the donor or through the terms of an appeal and fall into one of two sub-classes: restricted income funds or endowment funds.

CILIOPATHY ALLIANCE

Notes to the Financial Statements *(continued)*

Year ended 31 March 2026

3. Accounting policies *(continued)*

Incoming resources

All incoming resources are included in the statement of financial activities when entitlement has passed to the charity; it is probable that the economic benefits associated with the transaction will flow to the charity and the amount can be reliably measured. The following specific policies are applied to particular categories of income:

- income from donations or grants is recognised when there is evidence of entitlement to the gift, receipt is probable and its amount can be measured reliably.
- legacy income is recognised when receipt is probable and entitlement is established.
- income from donated goods is measured at the fair value of the goods unless this is impractical to measure reliably, in which case the value is derived from the cost to the donor or the estimated resale value. Donated facilities and services are recognised in the accounts when received if the value can be reliably measured. No amounts are included for the contribution of general volunteers.
- income from contracts for the supply of services is recognised with the delivery of the contracted service. This is classified as unrestricted funds unless there is a contractual requirement for it to be spent on a particular purpose and returned if unspent, in which case it may be regarded as restricted.

Resources expended

Expenditure is recognised on an accruals basis as a liability is incurred. Expenditure includes any VAT which cannot be fully recovered, and is classified under headings of the statement of financial activities to which it relates:

- expenditure on raising funds includes the costs of all fundraising activities, events, non-charitable trading activities, and the sale of donated goods.
- expenditure on charitable activities includes all costs incurred by a charity in undertaking activities that further its charitable aims for the benefit of its beneficiaries, including those support costs and costs relating to the governance of the charity apportioned to charitable activities.
- other expenditure includes all expenditure that is neither related to raising funds for the charity nor part of its expenditure on charitable activities.

All costs are allocated to expenditure categories reflecting the use of the resource. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs are apportioned between the activities they contribute to on a reasonable, justifiable and consistent basis.

Tangible assets

Tangible assets are initially recorded at cost, and subsequently stated at cost less any accumulated depreciation and impairment losses. Any tangible assets carried at revalued amounts are recorded at the fair value at the date of revaluation less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

CILIOPATHY ALLIANCE

Notes to the Financial Statements *(continued)*

Year ended 31 March 2026

3. Accounting policies *(continued)*

Tangible assets *(continued)*

An increase in the carrying amount of an asset as a result of a revaluation, is recognised in other recognised gains and losses, unless it reverses a charge for impairment that has previously been recognised as expenditure within the statement of financial activities. A decrease in the carrying amount of an asset as a result of revaluation, is recognised in other recognised gains and losses, except to which it offsets any previous revaluation gain, in which case the loss is shown within other recognised gains and losses on the statement of financial activities.

Depreciation

Depreciation is calculated so as to write off the cost or valuation of an asset, less its residual value, over the useful economic life of that asset

Impairment of fixed assets

A review for indicators of impairment is carried out at each reporting date, with the recoverable amount being estimated where such indicators exist. Where the carrying value exceeds the recoverable amount, the asset is impaired accordingly. Prior impairments are also reviewed for possible reversal at each reporting date.

For the purposes of impairment testing, when it is not possible to estimate the recoverable amount of an individual asset, an estimate is made of the recoverable amount of the cash-generating unit to which the asset belongs. The cash-generating unit is the smallest identifiable group of assets that includes the asset and generates cash inflows that largely independent of the cash inflows from other assets or groups of assets.

For impairment testing of goodwill, the goodwill acquired in a business combination is, from the acquisition date, allocated to each of the cash-generating units that are expected to benefit from the synergies of the combination, irrespective of whether other assets or liabilities of the charity are assigned to those units.

Financial instruments

A financial asset or a financial liability is recognised only when the charity becomes a party to the contractual provisions of the instrument.

Basic financial instruments are initially recognised at the amount receivable or payable including any related transaction costs.

Current assets and current liabilities are subsequently measured at the cash or other consideration expected to be paid or received and not discounted.

Debt instruments are subsequently measured at amortised cost.

Where investments in shares are publicly traded or their fair value can otherwise be measured reliably, the investment is subsequently measured at fair value with changes in fair value recognised in income and expenditure. All other such investments are subsequently measured at cost less impairment.

CILIOPATHY ALLIANCE

Notes to the Financial Statements *(continued)*

Year ended 31 March 2026

3. Accounting policies *(continued)*

Financial instruments *(continued)*

Other financial instruments, including derivatives, are initially recognised at fair value, unless payment for an asset is deferred beyond normal business terms or financed at a rate of interest that is not a market rate, in which case the asset is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.

Other financial instruments are subsequently measured at fair value, with any changes recognised in the statement of financial activities, with the exception of hedging instruments in a designated hedging relationship.

Financial assets that are measured at cost or amortised cost are reviewed for objective evidence of impairment at the end of each reporting date. If there is objective evidence of impairment, an impairment loss is recognised under the appropriate heading in the statement of financial activities in which the initial gain was recognised.

For all equity instruments regardless of significance, and other financial assets that are individually significant, these are assessed individually for impairment. Other financial assets are either assessed individually or grouped on the basis of similar credit risk characteristics.

Any reversals of impairment are recognised immediately, to the extent that the reversal does not result in a carrying amount of the financial asset that exceeds what the carrying amount would have been had the impairment not previously been recognised.

Defined contribution plans

Contributions to defined contribution plans are recognised as an expense in the period in which the related service is provided. Prepaid contributions are recognised as an asset to the extent that the prepayment will lead to a reduction in future payments or a cash refund.

When contributions are not expected to be settled wholly within 12 months of the end of the reporting date in which the employees render the related service, the liability is measured on a discounted present value basis. The unwinding of the discount is recognised as an expense in the period in which it arises.

4. Creditors: amounts falling due within one year

	2026 £	2025 £
Trade creditors	1,440	–
Accruals and deferred income	3,643	2,202
	<u>5,083</u>	<u>2,202</u>

CILIOPATHY ALLIANCE

Notes to the Financial Statements *(continued)*

Year ended 31 March 2026

5. Restricted Funds

Restricted funds represent monies received for specific purposes as determined by the donor or funding body and may only be applied towards those purposes.

During the year, the charity received £6,987 of restricted funding in relation to the TheRaCiL project. Expenditure of £3,832 was incurred on TheRaCiL project delivery during the year, resulting in an unspent balance of £3,155 at 31 March 2026.

Together with restricted funds of £1,477 brought forward from the previous year, total restricted funds carried forward at 31 March 2026 were £4,632.

	£
Restricted funds	
Balance at 1 April 2025	1,477
Restricted grant income	6,987
Restricted Expenditure	(3,832)
Balance at 31 March 2026	<u>4,632</u>

CILIOPATHY ALLIANCE

Detailed Statement of Financial Activities

Year ended 31 March 2026

			2026	2025
	Unrestricted funds £	Restricted funds £	Total funds £	Total funds £
Income and endowments				
Donations and legacies	686	—	686	1,477
Interest income	148	—	148	212
Restricted Grants	—	6,987	6,987	—
Total income	<u>834</u>	<u>6,987</u>	<u>7,821</u>	<u>1,689</u>
			2026	2025
	Unrestricted funds £	Restricted funds £	Total funds £	Total funds £
Expenditure on raising funds				
Fundraising Expenses	2,400	—	2,400	7,141
	<u>2,400</u>	<u>—</u>	<u>2,400</u>	<u>7,141</u>
			2026	2025
	Unrestricted funds	Restricted funds	Total funds	Total funds
Expenditure on charitable activities and governance				
TheRaCiL Project Delivery	—	3,832	3,832	—
Insurance	186	—	186	180
Governance Costs	3,668	—	3,668	—
Meetings & Conferences Costs	436	—	436	585
IT Software and Consumables	803	—	803	756
Printing, postage and stationery	214	—	214	296
Travelling	185	—	185	556
Subscriptions	532	—	532	480
General Expenses	—	—	—	358
Sundry expenses	15	—	15	—
	<u>6,039</u>	<u>3,832</u>	<u>9,871</u>	<u>3,211</u>
Net income and net movement in funds	<u>(7,605)</u>	<u>3,155</u>	<u>(4,450)</u>	<u>(8,663)</u>